James Keogh/Wostok Press

Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Press release

Promising MSF Research Highlights Immense Benefits, Need for Expanded Use of DR-TB Drug Combination

February 14, 2018

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease.
Press release

Governments Must Step Up the Use of Newer Drugs to Fight Multidrug-Resistant TB

October 13, 2017

People with drug-resistant tuberculosis (DR-TB) are still not receiving two newer tuberculosis (TB) drugs, bedaquiline and delamanid, which have shown improved cure rates for the disease, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.
In the News

Huffington Post: The G-20 Declaration Makes a Major Mention of the World’s Top Infectious Killer

July 11, 2017

This year's G20 declaration lays out the importance of promoting research and development to combat tuberculosis' (TB) "threat to public health and economic growth." Prior to the summit, Doctors Without Borders/Médecins Sans Frontières (MSF) urged G20 leaders to take action on drug-resistant infections, including TB. View External Media.
Press release

G20 Leaders Must Take Action to Protect Medical Facilities, Tackle Drug-Resistant Infections Including TB, and Better Prepare for Medical Emergencies

July 06, 2017

Ahead of the G20 summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.
Press release

Doctors Without Borders Urges Pharmaceutical Corporations to Release Clinical Data to Help Develop Urgently Needed New TB Regimens

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.
Field news

Swaziland: New Hope for Drug-Resistant TB Patients

February 23, 2017

"You see, I am healed," says Tholakele as she walks around her ward demonstrating her recovery. "Even my legs don't give me problems anymore. Now I can walk perfectly. I walk around the hospital; go out for fresh air and come back when I’m ready."

Tholakele, 39, has drug-resistant tuberculosis (DR-TB) and started treatment in May 2016 at the Moneni National TB Hospital, supported by Doctors Without Borders/Médecins Sans Frontières (MSF) in central Swaziland.
Press release

Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

January 24, 2017

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability
Press release

New MSF-Run Clinical Trial Starts Testing Better Treatment Options for People Living with DR-TB

January 19, 2017

NEW YORK, JANUARY 20, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began a new clinical trial this week in Uzbekistan to develop a radically improved course of treatment for drug-resistant tuberculosis (DR-TB).

The trial aims to find a treatment regimen for DR-TB that is drastically shorter, more effective, and causes fewer side effects than the current treatment options.
Slideshow

TB Patients in Tajikistan Celebrate New Treatment Access

November 07, 2016

In an attempt to break up the everyday routine for children undergoing tuberculosis treatment in Tajikistan, the MSF psychosocial team organizes celebration parties as part of MSF’s pediatric therapeutic play program.
Voice from the Field

South Africa: New Drug Offers Hope for Patients Fighting Drug-Resistant Tuberculosis

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

Pages